http://orcid.org/0000-0002-2852-061X
References
- Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowsi Z, Morris D, Aylward P, Woodlief LH, Topol EJ, Califf RM, Ross AM. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoker’s paradox” from the GUSTO-I trial, with angiographic insights. J Am Coll Cardiol. 1995;26:1222–1229. doi:10.1016/0735-1097(95)00299-5.
- Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, Jakubowski JA, Ojeh CK, Jeong YH, Tantry US, Baker BA. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013;62:505–512. doi:10.1016/j.jacc.2013.03.037.
- Sibbing D, Gross L. Smoking and Clopidogrel Response Revisited: hemoglobin Levels Explaining the Smoker’s Paradox. JACC Cardiovasc Interv. 2016;9:1691–1693. doi:10.1016/j.jcin.2016.06.042.
- Palmerini T, Calabro P, Piscione F, De Servi S, Cattaneo M, Maffeo D, Toso A, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Barozzi C, Tomasi L, Della Riva D, Mariani A, Taglieri N, Reggiani LB, Bianchi R, De Rosa R, Mariani M, Podda G, Genereux P, Stone GW, Angiolillo DJ. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. JACC Cardiovasc Interv. 2014;7:1117–1127. doi:10.1016/j.jcin.2014.04.020.
- De Servi S, Crimi G, Calabro P, Piscione F, Cattaneo M, Maffeo D, Toso A, Bartorelli A, Palmieri C, De Carlo M, Capodanno D, Barozzi C, Tomasi L, Della Riva D, Angiolillo DJ, Palmerini T. Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention. 2016;12:312–318. doi:10.4244/EIJV12I3A51.
- Kim YG, Suh JW, Kang SH, Park JJ, Yoon CH, Cho YS, Youn TJ, Chae IH, Choi DJ, Kim HS. Cigarette Smoking Does Not Enhance Clopidogrel Responsiveness After Adjusting VerifyNow P2Y12 Reaction Unit for the Influence of Hemoglobin Level. JACC Cardiovasc Interv. 2016;9:1680–1690. doi:10.1016/j.jcin.2016.05.036.
- Ciccarelli G, Barbato E, Golino M, Cimmino G, Bartunek J, Di Serafino L, Di Girolamo D, De Bruyne B, Wijns W, Golino P. Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. J Interv Cardiol. 2017;30:5–15. doi:10.1111/joic.12360.
- Cornel JH, Ohman EM, Neely B, Clemmensen P, Sritara P, Zamoryakhin D, Armstrong PW, Prabhakaran D, White HD, Fox KA, Gurbel PA, Roe MT, Investigators TA. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial. Am Heart J. 2014;168:76–87 e1. doi:10.1016/j.ahj.2014.04.011.